AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Evaluation of Functional Superiority of the Morrow eProgressive

RecruitingNAAges 45 Years - anyAllMorrow Eyewear
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Presbyopia is a common age-related condition where the eye loses its ability to focus on nearby objects, typically from around age 45. The standard correction is progressive addition lenses (PALs), but these have limitations: narrow viewing zones, peripheral distortion, and the need for unnatural head movements, which can affect comfort and safety. Morrow has developed an electronically adjustable progressive lens (Morrow eProgressive) that dynamically adapts its optical zones. This CE-marked device is already commercially available. This study compares its functional performance against standard PALs. Approximately 50 adults (โ‰ฅ45 years) will participate at three sites (Belgium and Italy). Each participant wears both glasses types for three weeks each, in random order. Researchers will measure head and eye movements during reading tasks, stair descent performance, and visual comfort

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Adults aged 45 or older, who are presbyopic in both eyes, with an inclusion criterium of minimum + 1.75 ADDition. * Suitable candidate for Morrow glasses * Willing and able to adhere to the study protocol and study procedures, and provide written consent prior to enrollment * Willing and able to strictly adhere to the 2 x 3-week spectacle-wearing schedule for all standard day-to-day activities, including a commitment to exclusive progressive wear of the assigned study spectacles (traditional PAL or Morrow eProgressive) throughout each respective study phase (temporary exceptions for sports or specific occasions are permitted using single-vision solutions only). * Current vision solution satisfaction below 8/10, as assessed by the study specific satisfaction questionnaire. Exclusion Criteria: * Individuals who do not yet require a reading addition for near tasks. * Distant BCVA worse than 20/25 (Snellen) or \>0.1 LogMar * Previous laser treatment for refractive correction. * Any previous refraction and/or intra-ocular surgery. * Any known systemic diseases affecting vision (e.g. diabetes, uncontrolled or unmedicated hypertension, autoimmune disease, inflammatory disease โ€ฆ ), at the discretion of the investigator * Associated strabismus (eyes not properly aligned) * Associated amblyopia (lazy eye) * Currently undergoing orthoptics therapy (exercises or treatments to fix eye movement problems or double vision) * Associated anisometropia \> 1.5 diopters
๐Ÿ’Š

What it tests

  • 3 weeks wearing of study device instead of their current wearing solution
๐Ÿ“

Where

3 sites
University Hospital Antwerp
Antwerp, Belgium
Meclinas
Mechelen, Belgium
Research Centre in Optics & Optometry (COMiB), University of Milano Bicocca
Milan, Italy
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy